Abstract
О bjective : to define the approach to the management of patients with the detected ASAP area. Materials and methods . In the time period from 2012 through 2015, 494 patients with previously negative biopsy and remaining suspicion of prostate cancer (PCa) were examined. The patients underwent repeat 24-core multifocal prostate biopsy with taking additional tissue samples from suspicious areas detected by multiparametric magnetic resonance imaging and transrectal ultrasound. An isolated ASAP area was found in 127 (25. 7 %) of the 494 examined men. All of them were offered to perform repeat target transrectal biopsy of this area. Targeted transrectal ultrasound guided biopsy of the ASAP area was performed in 56 (44.1 %) of the 127 patients, 53 of them being included in the final analysis. Results. PCa was diagnosed in 14 (26.4 %) of the 53 patients, their mean age being 64.4 ± 6.9 years. The average level of prostate-specific antigen (PSA) in PCa patients was 6.8 ± 3.0 ng/ml, in those with benign lesions – 9.3 ± 6.5 ng/ml; the percentage ratio of free/total PSA with PCa was 16.2 ± 7,8 %, with benign lesions – 23.3 ± 7.7 %; PSA density in PCa patients was 0.14 ± 0.07 ng/ml/cm3, in those with benign lesions – 0.15 ± 0.12 ng/ml/cm3. Therefore, with ASAP area being detected in repeat prostate biopsy samples, it is advisable that targeted extended biopsy of this area be performed.
Highlights
The paper makes an assessment of the clinicopathological significance of atypical small acinar proliferation (ASAP), detected in repeat transrectal prostate samples
The patients underwent repeat 24-core multifocal prostate biopsy with taking additional tissue samples from suspicious areas detected by multiparametric magnetic resonance imaging and transrectal ultrasound
Targeted transrectal ultrasound guided biopsy of the ASAP area was performed in 56 (44.1 %) of the 127 patients, 53 of them being included in the final analysis
Summary
The paper makes an assessment of the clinicopathological significance of atypical small acinar proliferation (ASAP), detected in repeat transrectal prostate samples. Под контролем ТРУЗИ с целевым (помимо систематических 24 биоптатов) взятием материала из подозрительных по данным мпМРТ и ультразвукового исследования зон предстательной железы / Under control of TRUS with targeted (apart from 24 systematic biopsy samples) sampling from suspicious zones of the prostate according to mpMRI and ultrasound examination Выполнение целевой биопсии зоны АМАП предстательной железы (n = 56 (44,1 %) из 127) / Targeted biopsy of the ASAP zone of the prostate (n = 56 (44.1 %) of 127)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have